The Conversation (0)
Knight Therapeutics released the voting results on a variety of the company’s decisions, from the annual meeting of shareholders.
Knight Therapeutics (TSX:GUD) released the voting results on a variety of the company’s decisions, from the annual meeting of shareholders.
As quoted in the press release:
Election of Directors
Each director nominee listed in the Management Information Circular dated March 21, 2017 (“Circular”) was elected as Director of the Corporation at the Meeting. Shareholders present in person or represented by proxy at the Meeting voted as follows:
DIRECTOR NOMINEE OUTCOME VOTES FOR % FOR VOTES WITHHELD % WITHHELD James C. Gale Elected 96,908,864 98.84% 1,135,250 1.16% Dr. Sarit Assouline Elected 97,835,461 99.79% 208,653 0.21% Jonathan Ross Goodman Elected 96,803,831 98.73% 1,240,283 1.27% Meir Jakobsohn Elected 96,097,771 98.01% 1,946,343 1.99% Robert N. Lande Elected 96,885,834 98.82% 1,158,280 1.18% Samira Sakhia Elected 94,108,859 95.99% 3,935,255 4.01% Sylvie Tendler Elected 96,883,334 98.82% 1,160,780 1.18% Adoption of a new stock option plan
The resolution to adopt a new stock option plan of the Corporation, as more particularly described in the Circular, was approved by a majority of the votes cast by the shareholders present or represented by proxy. Shareholders present in person or represented by proxy at the Meeting voted as follows:
VOTES FOR % FOR VOTES AGAINST % AGAINST 91,210,582 93.03% 6,833,532 6.97%
Source: www.marketwired.com
